What is the recommended dose of Zofran (ondansetron) for a 7-month-old infant weighing 8.4 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ondansetron Dosing for 7-Month-Old Infant (8.4 kg)

For a 7-month-old infant weighing 8.4 kg, ondansetron should be dosed at 0.15 mg/kg intramuscularly or intravenously, which equals 1.26 mg (approximately 1.3 mg), with a maximum dose of 16 mg. 1

Evidence-Based Dosing Recommendation

The most relevant and high-quality guideline evidence comes from the 2017 international consensus on Food Protein-Induced Enterocolitis Syndrome (FPIES), which provides specific ondansetron dosing for infants ≥6 months of age 1:

  • Dose: 0.15 mg/kg/dose 1
  • Route: Intramuscular or intravenous 1
  • Maximum: 16 mg/dose 1
  • For this 8.4 kg infant: 8.4 kg × 0.15 mg/kg = 1.26 mg (round to 1.3 mg)

Age-Specific Considerations

Critical caveat: Ondansetron is only recommended for infants ≥6 months of age 1. At 7 months, this infant meets the minimum age requirement. The guideline explicitly states this age restriction for safety reasons, as there is limited data in younger infants 1.

Clinical Context for Use

Ondansetron at this dose is indicated for 1:

  • Moderate FPIES reactions (>3 episodes of emesis with mild lethargy)
  • Severe FPIES reactions (>3 episodes of emesis with severe lethargy, hypotonia, or ashen/cyanotic appearance)
  • Can be considered for mild reactions in infants ≥6 months (1-2 episodes of emesis, no lethargy)

Route Selection

  • Intramuscular route is preferred when IV access is difficult or delayed 1
  • Intravenous route should be used when IV access is already established, particularly in severe presentations requiring fluid resuscitation 1

Important Safety Points

  • Do not use in infants <6 months old unless the situation is judged critical, due to extremely limited safety and efficacy data 1
  • Monitor for response over 4-6 hours from onset of reaction 1
  • Ondansetron may cause mild sedation, though this is generally well-tolerated 2, 3
  • The drug has a half-life of approximately 3.5 hours, which is slightly shorter in children compared to adults 3, 4

Common Pitfall to Avoid

Do not confuse this dosing with the influenza antiviral dosing tables found in multiple pediatric guidelines 1—those are completely unrelated to ondansetron (Zofran) dosing and pertain to oseltamivir, zanamivir, and other antivirals.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cetirizine Administration and Safety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ondansetron clinical pharmacokinetics.

Clinical pharmacokinetics, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.